About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli ...
Hedge Fund Alpha on MSN5h
Invest Like a Legend: Exploring the Stanley Druckenmiller PortfolioStanley Druckenmiller is a retired hedge fund manager of Duquesne Capital, which focuses on macro investment strategy. His fund constantly delivered high returns, and in 2010, when the fund failed to ...
Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...
Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...
FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...
The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...
For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...
The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...
Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback